• Ferrostatin-1 (Fer-1): Precise Inhibition of Ferroptosis in

  2026-07-14

  Ferrostatin-1 (Fer-1) is a selective, potent inhibitor of ferroptosis, functioning at nanomolar concentrations to block iron-dependent lipid peroxidation. It is a cornerstone tool for research into oxidative cell death mechanisms underlying cancer, neurodegeneration, and ischemic injury. APExBIO's Fer-1 (A4371) offers industry-standard purity and workflow compatibility for ferroptosis assays.

• PPM-18: Strategic iNOS and NF-κB Inhibition for Translationa

  2026-07-14

  Explore how PPM-18 (N-(1,4-dihydro-1,4-dioxo-2-naphthalenyl)-benzamide) redefines targeted immune modulation through selective NF-κB and iNOS inhibition. This article delivers mechanistic insights, experimental validation, and strategic guidance for translational researchers, bridging the latest literature and real-world protocol parameters for advanced inflammation and sepsis research.

• SD 169 (indole-5-carboxamide): Advanced p38 MAPK Inhibition

  2026-07-13

  SD 169 (indole-5-carboxamide) enables dual-action p38 MAPK inhibition for translational studies in inflammation, neuroregeneration, and type 1 diabetes research. This guide details evidence-based workflows, troubleshooting strategies, and protocol enhancements that maximize the compound’s impact across advanced cellular and disease models.

• SB 202190: Precision p38 MAPK Inhibition in Neuroinflammatio

  2026-07-13

  Explore how SB 202190, a potent p38 MAP kinase inhibitor, is transforming inflammation research with advanced insights into neuroinflammatory mechanisms. This article uniquely connects recent astrocyte-microglia crosstalk findings to practical assay design and disease modeling.

• TSPAN18 Stabilizes STIM1 to Drive Bone Metastasis in Prostat

  2026-07-12

  Zhou et al. reveal that TSPAN18 directly binds to and stabilizes STIM1, preventing its ubiquitination by TRIM32 and thereby promoting store-operated calcium entry (SOCE). This mechanism accelerates bone metastasis in prostate cancer models, highlighting TSPAN18 as a promising molecular target for future therapeutic strategies.

• IBDV VP3 Targets IRF7 for Proteasome Degradation to Evade Im

  2026-07-10

  This study uncovers how infectious bursal disease virus (IBDV) exploits its VP3 protein to promote the proteasome-dependent degradation of interferon regulatory factor 7 (IRF7), thereby suppressing type I interferon signaling and enhancing viral replication in chicken cells. These findings provide mechanistic insight into viral immune evasion strategies and highlight the importance of the ubiquitin-proteasome system in host-pathogen interactions.

• Hepatic sEH Suppresses Nrf2 to Promote Osteoclastogenesis in

  2026-07-09

  This study reveals a novel liver-bone regulatory axis in osteoporosis, demonstrating that hepatic soluble epoxide hydrolase (sEH) promotes osteoclast differentiation by suppressing the Nrf2 antioxidant pathway. By elucidating the impact of altered epoxyeicosatrienoic acid metabolism on redox balance and bone health, the findings open new avenues for chronic inflammation and osteoporosis research.

• U0126-EtOH: Precision MEK1/2 Inhibitor for MAPK/ERK Modulati

  2026-07-09

  U0126-EtOH delivers highly selective MEK1/2 inhibition for dissecting the MAPK/ERK pathway in both neuroprotection and inflammation models. This article translates mechanistic advances from bench research into actionable protocols, troubleshooting, and strategic applications for cutting-edge oxidative stress and leukemia studies.

• Cefotaxime in Research: Resistance Dynamics and Experimental

  2026-07-08

  Explore how Cefotaxime, a third-generation cephalosporin antibiotic, empowers advanced research into antimicrobial resistance and bacterial infection models. This article offers novel insights into gene transfer dynamics and practical assay design, setting it apart from existing resources.

• SB203580: Advancing p38 MAPK Inhibition in Translational Pai

  2026-07-08

  Explore how SB203580, a selective p38 MAPK inhibitor, is revolutionizing translational research in neuropathic pain and neuroinflammation. This article bridges mechanistic insight, experimental best practices, and strategic guidance for leveraging SB203580 in state-of-the-art disease modeling, with a focus on recent findings and workflow integration.

• CYP2B6 Downregulation in Glioblastoma via ATF5 Peptide Targe

  2026-07-07

  The reference study demonstrates that a cell-penetrating dominant-negative ATF5 peptide effectively downregulates CYP2B6 expression in glioblastoma cells. This finding offers a new approach for modulating tumor drug metabolism, which could enable more personalized and safer therapies for glioblastoma patients.

• Bufalin as a Precision Tool: Redefining STK33 Targeting in T

  2026-07-07

  Explore how Bufalin, a cardiotonic steroid, enables highly selective targeting of STK33 in triple-negative breast cancer models. This article provides advanced scientific insight into Bufalin's mechanism as a molecular glue degrader and its impact on apoptosis induction in cancer cells.

• SD 169 (indole-5-carboxamide): Optimizing p38 MAPK Pathway A

  2026-07-06

  SD 169 (indole-5-carboxamide) empowers researchers to achieve precise, reproducible inhibition of the p38 MAPK signaling pathway in both immunology and neurobiology studies. Its dual-action mechanism and robust selectivity streamline experimental workflows in apoptosis, type 1 diabetes, and axonal regeneration research, as underscored by recent conformational biology findings.

• SB 202190: Precision p38 MAP Kinase Inhibitor for Disease Mo

  2026-07-06

  SB 202190 offers nanomolar potency and ATP-competitive selectivity, enabling researchers to precisely dissect MAPK signaling in complex models of inflammation, apoptosis, and cancer. Its robust performance and reproducibility, as highlighted by both foundational studies and recent mechanistic insights, make it the benchmark p38 MAP kinase inhibitor for translational research.

• FoxM1-Engineered BMSCs Enhance ARDS Therapy via Wnt/β-Cateni

  2026-07-05

  Luo et al. demonstrate that overexpression of FoxM1 in bone marrow mesenchymal stem cells (BMSCs) significantly improves their therapeutic efficacy in acute respiratory distress syndrome (ARDS) by promoting endothelial protection through Wnt/β-catenin pathway activation. The study clarifies that this benefit is mediated mainly by paracrine effects, not direct differentiation into alveolar epithelial cells, and shows the mechanistic role of Wnt signaling using a tankyrase inhibitor.

16624 records 1/1109 page Next 12345 下5页 Last page